PPAR Research

Research Article

The Impact of PPAR Genetic Variants on IBD Susceptibility and IBD Disease Course

Table 11

Haplotype and diplotype distribution in IBD cases with and without disease activity.
Subjects includedH1 (CC)H2 (CT)H3 (GC)H4 (GT)
IBD N (%)4882.9 (84.6)3.1 (3.2)2.1 (2.2)9.9 (10.1)0.83
OR (C.I.)0.99 (0.53–1.83)0.65 (0.19–2.21)0.88 (0.2–3.96)1.29 (0.6–2.74)
Controls (b)191323.6 (84.7)18.4 (4.8)9.4 (2.5)30.6 (8.0)
UC N (%)1831.0 (86.0)1.0 (2.9)0.0 (0.1)4.0 (11.0)0.74
OR (C.I.)1.16 (0.42–3.18)0.67 (0.08–5.23)0.04 (0.0–749.8)1.3 (0.41–4.09)
Controls (b)108181.8 (84.2)9.2 (4.3)6.2 (2.9)18.8 (8.7)
CD N (%)3151.9 (83.7)2.1 (3.4)2.1 (3.4)5.9 (9.5)0.72
OR (C.I.)0.88 (0.39–1.95)0.6 (0.13–2.76)1.79 (0.31–10.5)1.37 (0.49–3.86)
Controls (b)83141.8 (85.4)9.2 (5.5)3.2 (1.9)11.8 (7.1)
D1 (CC/CC)D2 (CC/GT)D3 (GC/CT)D4 (CC/CT)
IBD N (%)4835.0 (71.4)8.9 (18.1)NP2.0 (4.1)
OR (C.I.)1.04 (0.52–2.08)1.31 (0.57–3.01)0.44 (0.10–1.95)
Controls (b)191135.0 (70.7)27.6 (14.4)NP17.0 (8.9)
UC N (%)1814.0 (77.8)3.0 (16.4)NP0.0 (0)
OR (C.I.)1.54 (0.47–5.03)1.07 (0.28–4.13)—
Controls (b)10875.0 (69.4)16.8 (15.5)NP9.0 (8.3)
CD N (%)3121.0 (67.7)5.9 (19.0)NP2.0 (6.5)
OR (C.I.)0.81 (0.33–1.97)1.57 (0.52–4.72)0.65 (0.13–3.23)
Controls (b)8360.0 (72.3)10.8 (13.0)NP8.0 (9.6)
D5 (CC/GC)D6 (CT/GT)D7 (GT/GT)D8 (GC/GT)
IBD N (%)2.0 (4.1)1.0 (2.0)0.0 (0)NP0.70
OR (C.I.)0.86 (0.18–4.12)——
Controls9.0 (4.7)1.0 (0.5)1.0 (0.5)NP
UC N (%)0.0 (0)1.0 (5.6)0.0 (0)NP0.16
OR (C.I.)———
Controls6.0 (5.6)0.0 (0)1.0 (0.9)NP
CD N (%)2.0 (6.5)0.0 (0)NPNP0.80
OR (C.I.)1.84 (0.29–11.57)—
Controls3.0 (3.6)1.0 (1.2)NPNP
OR: odds ratio; CI: confidence interval; N: absolute number; H1–H4: haplotype 1—haplotype 4; D1–D8: diplotype 1—diplotype 8; NP: predicted to not appear in the respective case or control group; (a) values calculated with FAMHAP; (b) the term “controls” denotes here the respective patient subgroup (IBD/UC/CD) without the respective ongoing disease activity pattern investigated.